[Industry]

Shanghai-based Harbour BioMed Deepens US Partnership

by Lu Feiran
January 22, 2026
Share Article:

Shanghai-based Harbour BioMed (stock sticker: 2142.HK) has taken an equity stake in US biotech firm Spruce Biosciences, signaling a shift by Chinese drug developers toward deeper strategic partnerships beyond one-off licensing deals. According to a comopany filing with the Hong Kong Stock Exchange, Harbour exercised warrants granted under a prior licensing agreement, acquiring approximately a 3.8% stake in Spruce.

The warrants were issued when Harbour's subsidiary, HBM Alpha Therapeutics, entered into a licensing agreement last year that granted Spruce the rights to develop and commercialize Harbour's early-stage therapy for rare hormone disorders. Harbour founder and chief executive Wang Jingsong said the move represents "a significant milestone," marking a transition from a conventional licensor-licensee relationship to a more strategic partnership.


#Shanghai
Share Article:

In Case You Missed It...

Global Tech Selloff Snares Chinese Stocks Amid Doubts About the AI Boom
FEATURED
[MONEY]
Global Tech Selloff Snares Chinese Stocks Amid Doubts About the AI Boom
@ Wang YanlinLineNov 21, 2026
Shanghai, Singapore Ink 16 Deals, Advancing Cross-border Finance, Innovation and Cultural Ties
[News]
Shanghai, Singapore Ink 16 Deals, Advancing Cross-border Finance, Innovation and Cultural Ties
Highlights include a landmark QFLP tech fund, DBS-backed startup platform, and a new cultural agreement between Shanghai Art Museum and Singapore's Asian Civilisations Museum.
Asher Levine, The LA Designer for Superstars in Shanghai
[Captains of Industry]
Asher Levine, The LA Designer for Superstars in Shanghai
The designer behind Lady Gaga, Beyoncé, Lisa and more comes to Shanghai.
Daily Buzz: 20 November 2026
[Daily Buzz]
Daily Buzz: 20 November 2026
A quick look at the market, economic and business news making headlines in China.
AISHAISH